Organization | Russian Foundation of Technological Development

Russian Foundation of Technological Development Report issue

Academic/Hospital Phase 3

Founded: Moscow Russian Federation (1991)

Organization Overview

First Clinical Trial

2012

NCT01782274

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (5)

allogeneic hematopoietic stem cells (Hemacord) (3 trials)

autologous hematopoietic stem cells (3 trials)

cytotoxic t cells (3 trials)

dendritic cells loaded with brain metastases (3 trials)

dendritic cells loaded with glioblastoma (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Glioblastoma (Phase 3)

Lung Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 5